European Medicines Agency’s COMP and Paediatric Committee’s conditions for drug development compared
Read
Orphan drugs development challenges and solutions
Read
Orphan drug development incentives: a review of the regulatory framework
Read
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018
Read
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018
Read
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018
Read
Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation for
Read
Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation for
Read
Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation for
Read
Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation for
Read
Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation for
Read
Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation for
Read
FDA September 2018 marketing approvals of orphan drugs
Read
FDA October 2018 marketing approvals of orphan drugs
Read
FDA November 2018 marketing approvals of orphan drugs
Read
FDA December 2018 marketing approvals of orphan drugs
Read